BMSSC
KYMR icon

B. Metzler seel. Sohn & Co’s Kymera Therapeutics KYMR Stock Holding History

B. Metzler seel. Sohn & Co’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.39M Hold
12,083
– – 0.01% 506
2026
Q1 		$1.01M Sell
12,083
-3,524
-23% -$279K 0.01% 544
2025
Q4 		$1.21M Buy
+15,607
New +$1.05M 0.01% 510
2023
Q3 		– Sell
-16,608
Closed -$382K – 741
2023
Q2 		$382K Buy
+16,608
New +$476K 0.01% 613

Other funds holding KYMR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $526M AUM 175.27% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
TD Asset Management
TD Asset Management Toronto, Ontario, Canada $115B AUM 41.58% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
EHI
Eagle Health Investments Greenwich, Connecticut $603M AUM 111.06% 1-Year Est. Return

B. Metzler seel. Sohn & Co's KYMR Position: Q2 2026 in Review

B. Metzler seel. Sohn & Co held its Kymera Therapeutics (KYMR) position steady in Q2 2026 at 12,083 shares worth $1.39M. The position accounts for 0.01% of the portfolio, ranked #506.

B. Metzler seel. Sohn & Co first reported a position in KYMR in Q2 2023 and has held it in 4 quarters since. 117 funds tracked by Wall St. Rank hold KYMR as of Q2 2026.

  • B. Metzler seel. Sohn & Co held 12,083 shares of Kymera Therapeutics worth $1.39M as of Q2 2026.
  • B. Metzler seel. Sohn & Co left its Kymera Therapeutics share count unchanged in Q2 2026.
  • Kymera Therapeutics made up 0.01% of B. Metzler seel. Sohn & Co's portfolio in Q2 2026, its #506 holding.
  • B. Metzler seel. Sohn & Co first reported a position in Kymera Therapeutics in Q2 2023 and has held it in 4 quarters since.
  • 117 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2026.

Based on B. Metzler seel. Sohn & Co's 13F filing for Q2 2026, filed 11 Aug 2026.